Abcam, ab283026, Human MAVS knockout A549 cell lysate

Size: 1Kit
MAVS KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 101 bp deletion in exon 5.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 101 bp deletion in exon 5,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-MAVS, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MAVS also known as mitochondrial antiviral-signaling protein is a critical adaptor protein involved in the innate immune response to viral infections. This protein with a molecular weight of approximately 56 kDa is expressed on the mitochondrial membrane. It plays a major role in antiviral defense by transmitting signals from cytosolic pattern recognition receptors like RIG-I-like receptors to initiate downstream immune responses. MAVS can also be referred to as IPS-1 VISA or CARDIF in scientific literature.
Biological function summary
The MAVS protein activates important signaling cascades to produce type I interferons and other cytokines which are essential in the antiviral response. MAVS forms a complex with other proteins on the mitochondrial membrane helping to coordinate a rapid immune reaction to viral pathogens. It acts by amplifying the signal from RIG-I and MDA5 facilitating their role in the recognition of viral RNA. By recruiting downstream signaling molecules MAVS enables the activation of transcription factors like IRF3 and NF-kB.
Pathways
MAVS plays a central role in the signaling pathways that regulate innate immunity including the RIG-I-like receptor signaling pathway and the NF-kB pathway. It interacts with various proteins such as TRIF and STING in the pathways to modulate immune responses. These pathways help trigger the production of antiviral substances and maintain homeostasis within the body's defense mechanisms. MAVS provides a platform for the assembly of signaling complexes which are necessary for the propagation and amplification of the immune response signal.
MAVS is associated with conditions such as viral infections and autoimmune diseases. Dysregulation of MAVS activity has been linked to systemic lupus erythematosus where abnormal immune signaling may occur. MAVS also has connections with other proteins such as TRAF3 and TRAF6 which contribute to disease pathogenesis. Understanding the role of MAVS in these conditions may provide insights into therapeutic targets for improving disease outcomes.